Abstracts S37 sFlt-1) traps circulating VEGF and is therefore anti-angiogenic. An emerging concept is that adenosine, known for its cardioprotective effects, is a major factor driving angiogenesis, thus contributing to the repair of the ischemic heart. The aims of the present study were (1) to characterize the effects of adenosine on VEGF and sFlt-1, (2) to determine which subtype(s) of adenosine receptor (A1, A2a, A2b, A3) promote these effects.
Methods -Human primary cardiac À broblasts, myoÀ broblasts, and blood monocyte-derived macrophages were treated with adenosine (10 õm) or adenosine analogs, and/or LPS (100 ng/ml). In vitro formation of microtubules by human coronary artery cells (HCAEC) was used as an angiogenesis assay. Transgenic mice with cardiacspeciÀ c and inducible overexpression of A1 and A2a receptors were used. Wild type (WT) and A3 adenosine receptor knocked-out mice were subjected to transverse aortic constriction (TAC). ELISA, realtime quantitative PCR, Á ow cytometry and immunoblotting were used to measure levels of VEGF, HIF-1α and sFlt-1.
Results -Adenosine increased VEGF mRNA and protein expression by human primary À broblasts, myoÀ broblasts and macrophages (22-fold increase in adenosine-and LPS-treated macrophages, P<0.0001). Up-regulation of VEGF by adenosine was replicated using agonists of A2a (C141) and A3 (IB-MECA) receptors, and inhibited by antagonists of A2a (SCH58261) and A2b (MRS1754) receptors. sFlt-1 production induced by LPS was decreased by 43 % in the presence of adenosine (P=0.006). Adenosine enhanced the formation of a network of microtubules by HCAEC and this effect was dampened in the presence of VEGF-blocking antibody. Over-expression of the A2a receptor in mice enhanced VEGF and HIF-1α expression. TAC increased VEGF and HIF-1α expression in the heart, an effect inhibited in A3-deÀ cient mice.
Conclusion -Adenosine plays a major role in angiogenesis through up-regulation of the pro-angiogenic VEGF and down-regulation of the anti-angiogenic sFlt-1. These effects appear to be mainly mediated by the A2a receptor. Our results suggest that both A2a and A3 receptors play signiÀ cant roles in adenosine-mediated angiogenesis. Angiotensin II type 2 receptor (AT2R) stimulation is thought to induce vasodilation and apoptosis. Nevertheless, its role remains controversial. In hypertension and aging, AT2R might promote vasoconstriction and cell growth. In cancer cells, AT2R is highly expressed but its role remains poorly understood. Thus, we investigated the role of AT2R in tumor growth, hypothesizing that AT2R affects cell proliferation and/or tumor vascularization.
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PHARMACOLOGICAL BLOCKADE OF ANGIOTENSIN II TYPE 2 RECEPTOR INHIBITS TUMOR GROWTH DECREASING CELL PROLIFERATION AND TUMOR VASCULARIZATION
Tumor induction by 3-methylcholanthrene was signiÀ cantly delayed in AT2R knockout mice, suggesting a role for AT2R in tumor initiation.
Tumor growth after subcutaneous injection of LL/2 cancer cells in C57/BL6 mice treated with PD123,319, an AT2R antagonist, was decreased when PD123,319 was given at an early stage, suggesting that AT2R is also involved in tumor promotion. In vitro proliferation of LL/2 cells was reduced by PD123,319 with a signiÀ cant decrease in Ki67 expression and ERK1/2 phosphorylation. In addition, tumor vascular density, measured by CD31 labeling and angiogenesis using the aortic ring assay on Matrigel®, were reduced by PD123,319 and in AT2R-null mice. Therefore, we uncovered a novel mechanism by which AT2R promotes tumor development favoring both malignant cancer cell proliferation and tumor angiogenesis. Thus, blocking AT2R could be a new approach in tumor therapy. Increased permeability of, and bleeding from, microvessels within the atheromatous arterial wall participate in atherothrombosis progression. The VEGF family and angiopoietin system components govern microvessel development and maturation. Serine protease activities are proportional to atherothrombosis progression and linked to intraplaque hemorrhage. Here we investigated the relationship between angiogenic factors and proteases in human hemorrhagic and non-hemorrhagic atheromatous carotid samples by immunohistochemistry, in situ hybridization and ELISA. Plaque activity of plasmin and leukocyte elastase and proteolysis of angiogenic factors by plaque extracts were determined. Smooth muscle cell migration induced by hemorrhagic and nonhemorrhagic plaques was assessed. The absence of á-actin-positive cells characterized microvessels in hemorrhagic areas in spite of similar expression of VEGF and angiopoietin system components in microvessels of hemorrhagic and non-hemorrhagic areas. However, VEGF, PlGF and angiopoietin-1 levels were signiÀ cantly decreased in hemorrhagic compared to non-hemorrhagic plaques, whereas angiopoietin-2 did not change and soluble Tie-2 levels increased. Consequently, smooth muscle cell migration stimulatory activity of hemorrhagic plaques was reduced. Recombinant PlGF, VEGF and angiopoietin-1 added to plaque extracts were only degraded by hemorrhagic lesions. This proteolysis was prevented by inhibitors of plasmin and elastase, whose activity was increased in hemorrhagic plaques. No degradation was observed for angiopoietin-2. Decreased angiogenic factor levels caused by proteolysis may destabilize plaque microvessels via impairment of mural cell recruitment, thus leading to a vicious circle of intraplaque hemorrhages and lesion progression.
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PROTEOLYSIS OF ANGIOGENIC FACTORS ASSOCIATED WITH INTRAPLAQUE HEMORRHAGES IN HUMAN ATHEROTHROMBOTIC PLAQUES
